PharmaShots | Incisive News in 3 Shots

Subscribe Now

GMFM-E

Aeglea Biotherapeutics Achieves Primary Endpoint in P-III study of Pegzilarginase in patients with Arginase 1 Deficiency

Aeglea Biotherapeutics Achieves Primary Endpoint in P-III study of Pegzilarginase in patients with Arginase 1 Deficiency

December 6, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us